Combined VEGFR and CTLA-4 blockade increases the antigen-presenting function of intratumoral DCs and reduces the suppressive capacity of intratumoral MDSCs

Stephanie Du Four, Sarah K Maenhout, Simone P Niclou, Kris Thielemans, Bart Neyns, Joeri L Aerts

1Laboratory of Molecular and Cellular Therapy, Vrije Universiteit Brussel, Laarbeeklaan 103E, 1090, Brussels, Belgium; 2Department of Medical Oncology, UZ Brussel, Laarbeeklaan 101, 1090, Brussels, Belgium; 3NORLUX Neuro-Oncology Laboratory, Luxembourg Institute of Health (LIH), Luxembourg

Received April 11, 2016; Accepted April 24, 2016; Epub November 1, 2016; Published November 15, 2016

Abstract: Melanoma brain metastases (MBM) occur in 10% to 50% of melanoma patients. They are often associated with a high morbidity and despite the improvements in the treatment of advanced melanoma, including immunotherapy, patients with MBM still have a poor prognosis. Antiangiogenic treatment was shown to reduce the immunosuppressive tumor microenvironment. Therefore we investigated the effect of the combination of VEGFR- and CTLA-4 blockade on the immune cells within the tumor microenvironment. In this study we investigated the effect of the combination of axitinib, a TKI against VEGFR-1, -2 and -3, with therapeutic inhibition of CTLA-4 in subcutaneous and intracranial mouse melanoma models. The combination of axitinib with αCTLA-4 reduced tumor growth and increased survival in both intracranial and subcutaneous models. Investigation of the splenic immune cells showed an increased number of CD4+ and CD8+ T cells after combination treatment. Moreover, combination treatment increased the number of intratumoral dendritic cells (DCs) and monocytic myeloid-derived suppressor cells (moMDSCs). When these immune cell populations were sorted from the subcutaneous and intracranial tumors of mice treated with axitinib+αCTLA-4, we observed an increased antigen-presenting function of DCs and a reduced suppressive capacity of moMDSCs on a per cell basis. Our results suggest that the combination of antiangiogenesis and checkpoint inhibition can lead to an enhanced antitumor effect leading to increased survival. We found that this effect is in part due to an enhanced antitumor immune response generated by an increased antigen-presenting function of intratumoral DCs in combination with a reduced suppressive capacity of intratumoral moMDSCs.

Keywords: MDSC, melanoma brain metastases, antiangiogenesis, CTLA-4 blockade, DCs, tumor microenvironment

Introduction

Patients with advanced melanoma have a high risk of developing brain metastases. The frequency of melanoma brain metastases (MBM) in these patients ranges from 10% to 50% and autopsy series suggest even higher frequencies (66% to 75%) [1].

Over the past few years the overall survival (OS) of advanced melanoma patients has improved with the introduction of BRAF- and MEK-inhibitors (resp. dabrafenib, vemurafenib and trametinib) and immune checkpoint blockers including monoclonal antibodies against Cytotoxic T Lymphocyte Antigen 4 (CTLA-4) and Programmed Death 1 (PD-1) (resp. ipilimumab and nivolumab, pembrolizumab) [2-7]. In patients with MBM, positive for BRAF V600 mutations, treatment with dabrafenib and vemurafenib led to objective response rates (ORR) of respectively 30% and 42% and median OS (mOS) of approximately 8 months and 5.2 months respectively, demonstrating their intracranial activity [8, 9]. Treatment with ipilimumab led to a mOS of 7 months and 3.7 months in respectively asymptomatic MBM patients and symptomatic corticosteroid-dependent MBM patients [10]. Hence, despite these promising results in advanced melanoma, the prognosis of patients with MBM still remains poor.
Over the past few years it has been shown that antiangiogenic treatment has beneficial effects on tumor growth, but also has favorable effects on antitumor immunity. This is due to the fact that elevated levels of circulating Vascular Endothelial Growth Factor (VEGF) exert negative effects on immune cells through several mechanisms, including suppression of dendritic cell (DC) maturation, promotion of regulatory T cell (Treg) proliferation, attraction of myeloid-derived suppressor cells (MDSCs) and induction of a pro-angiogenic and immunosuppressive M2-like phenotype in tumor-associated macrophages (TAMs). In addition, the imbalance of the VEGF-VEGFR-signaling pathway present in the tumor microenvironment results in leaky immature blood vessels and high interstitial pressure limiting influx of immune cells in the tumor [11-14]. However, it has been shown that VEGF-VEGFR-blockade not only induces maturation of immature blood vessels and leads to a reduction in interstitial pressure, but also reduces the number of MDSCs, repolarizes the TAMs to an M1-like phenotype and increases intratumoral T-cell infiltration [11, 15]. Additionally, we have previously shown in subcutaneous and intracranial mouse melanoma models that VEGFR-blockade reduces the suppressive capacity of monocytic MDSCs (moMDSCs) and induces an antigen-presenting capacity in these cells [16].

The effect of CTLA-4 blockade on MDSCs has not been extensively investigated. In melanoma patients a higher number of circulating MDSCs was observed and their number increases with metastatic spread. Treatment with ipilimumab decreased the number of circulating MDSCs, more specifically the granulocytic MDSCs (grMDSCs), and reduced numbers of MDSCs were correlated with improved outcome of melanoma patients. In addition, ipilimumab reduced the arginase-1 production of these grMDSCs, which is their most commonly described suppressive mechanism [17-19].

Therefore we investigated whether the combination of axitinib, a tyrosine kinase inhibitor (TKI) against VEGFR-1, -2 and -3, with a monoclonal antibody blocking CTLA-4 synergistically affects tumor growth and the frequency and function of several immune cell populations, specifically MDSCs, in subcutaneous and intracranial melanoma mouse models.

Material and methods

Tumor cell lines

The mouse melanoma cell line B16F1 was purchased from the American Type Culture Collection (ATCC) and was cultured in Dulbecco’s Modified Eagle Medium (DMEM, Sigma) supplemented with 5% fetal clone I (FCI), 100 U/ml penicillin, 100 µg/ml streptomycin, 2 mM L-glutamine, 1 mM sodium pyruvate and non-essential amino acids. To allow in vivo bioluminescence imaging of intracranial tumors, B16F1 cells were transduced with a lentiviral construct encoding both tNGFR and Fluc (pHR trip CMV luc2-ires-tNGFR SIN, described in Goyvaerts et al.) [20]. Stable and highly Fluc positive B16F1 cells were subsequently enriched by cell sorting using the expression levels of the tNGFR protein as a reference. We refer to the stable luciferase-expressing cell line used as B16F1-Fluc. The growth rate of B16F1-Fluc cells was similar to that of the parental line. No full authentication of the cell lines was carried out. Cell lines were tested for their known characteristics including expression of antigens and MHC molecules by reverse transcriptase PCR or flow cytometry and their in vitro and in vivo growth characteristics were closely monitored.

Mice and tumor models

Female and male, 6- to 12-week-old C57BL/6 (CD45.2 congenic) and C3H mice were purchased from Charles River (L’Arbresle Cedex, France). Pmel-1 TCR (T cell receptor transgene specific for the mouse homologue pmel of the human premelanosome protein gp100) transgenic mice were kindly provided by Dr. Thorwald van Hall (Leiden University Medical Center) and sequentially bred in house. The Vβ-13-pmel-1 TCR recognizes an epitope of the gp100 melanoma/melanocyte differentiation antigen present on the B16F1 melanoma. All animals were bred, housed and handled according to the European guidelines for animal experimentation. All experiments were reviewed and approved by the ethical committee for use of laboratory animals of the Vrije Universiteit Brussel. For the induction of subcutaneous tumors, mice were anesthetized by inhalation of isoflurane (Abbvie) and inoculated with 5 x 10^5 B16F1 tumor cells in the lower...
Combined VEGFR-CTLA-4 blockade and intratumoral DCs and MDSCs

back. For the induction of intracranial tumors, mice were anesthetized through intraperitoneal injection of ketamine (70 mg/kg; Ceva) and xylazine (10 mg/kg; Bayer) and 1 x 10⁴ B16F1 cells or B16F1-FLuc cells were stereotactically implanted into the brain (1 mm anterior to the bregma and 2 mm to the right of the midline suture at a depth of 2.5 mm).

_Treatment of tumor-bearing mice with axitinib_

Axitinib was kindly provided by Mike Sullivan from Pfizer. For the subcutaneous tumor model, mice were randomly divided into a control group and a treatment group. When tumors reached a volume of approximately 100 mm³, mice were dosed orally with vehicle or axitinib (25 mg/kg), respectively. Mice were treated by oral gavage, bid, for a period of 7 days. Mice were injected intraperitoneally with 100 µg anti-mouse CTLA-4 (5 mg/kg, clone 9H10) or hamster IgG1 isotype control (both from BioXCell) on day 2, 4 and 6 of axitinib treatment for _in vivo_ assays and on day 2, 4, 6 and 8 for survival experiments.

Tumors were measured every 2 days and tumor volume was calculated using the following formula: V = ([smallest diameter]² x largest diameter)/2. Mice were sacrificed when tumors reached a volume of 2,500 mm³. For the intracranial tumor model, 7 days after tumor inoculation, mice were randomly divided into a control group and a treatment group and were treated as described above. Tumor growth was measured by means of _in vivo_ bioluminescence. Mice were imaged every three days. Before and during imaging, mice were anesthetized with isoflurane (2%). Prior to imaging, 50 µL of 30 mg/ml luciferase substrate, D-Luciferin (Promega), in 0.9% NaCl (Braun) was injected intravenously. Mice were shaved over the intracranial injection site of tumor cells to minimize the amount of light absorbed by the black fur. A cooled charge coupled device camera apparatus (PhotonImager, Optima, Biospace lab) was used to detect photon emission from tumor-bearing mice with an acquisition time of 5 min. Analysis was performed as previously described [21].

_Phenotypical characterization of immune cells_

In order to evaluate the phenotype of different immune cell populations, cells derived from the spleen or tumor of vehicle- or axitinib-treated mice were stained with the following antibodies: phycoerythrin (PE)-Cy7-conjugated anti-mouse CD3 (BioLegend), Alexa Fluor 700 (AF700)-conjugated anti-mouse CD4 (BD Biosciences), AF647-conjugated anti-mouse CD8 (BioLegend), Horizon V450-conjugated anti-mouse CD45 (BD Biosciences), peridinin chlorophyll protein (PerCP)-Cy5.5-conjugated anti-mouse CD4 (BD Biosciences), PE-conjugated anti-mouse CD25 (eBioscience), AF647-conjugated anti-mouse CD11c (BioLegend), PE-conjugated anti-mouse CD11b (BD Biosciences), fluorescein isothiocyanate (FITC)-conjugated anti-mouse CD86 (BD Biosciences), biotin-conjugated anti-mouse CD80 (BD Biosciences) with streptavidin-allophycocyanin (APC)-H7 antibody (BD Biosciences), FITC-conjugated anti-mouse CD11b (BD Biosciences), AF647-conjugated anti-mouse Ly6G (BioLegend) and PE-Cy7-conjugated anti-mouse Ly6C (BioLegend).
Restimulation assay

In order to evaluate if there were antigen-specific T cells present in the spleen of tumor-bearing mice, splenocytes were isolated, labeled with 0.5 μM CellTrace® Violet (Invitrogen) and seeded in 96-well plates at 2 x 10^5 cells per well in the presence of TRP-2-peptide at a concentration of 5 μM (Sigma-Aldrich). After 3 days, proliferation of CD4^+ and CD8^+ T cells was analyzed by flow cytometry by staining with PerCPCy5.5-conjugated anti-mouse CD3 (BioLegend), AF700-conjugated anti-mouse CD4 (BD Biosciences) and APCH7-conjugated anti-mouse CD8 (BD Biosciences) antibodies. In addition, supernatants collected 3 days after co-culture were subjected to enzyme-linked immunosorbent assay (ELISA) to quantify cytokine secretion.

Purification of MDSCs from spleen and tumor and DCs from the tumor

To study the function of splenic MDSCs, the CD11b^+ fraction was enriched by MACS sorting using CD11b^+ Microbeads (Miltenyi Biotec) and to assess the function of tumor-infiltrating MDSCs the CD45^+ fraction was enriched by MACS sorting using CD45^+ MicroBeads (Miltenyi Biotec). These enriched CD11b^+ cells (spleen) or CD45^+ cells (tumor) were then stained with Brilliant Violet 605-conjugated anti-CD11b (BD Biosciences), APC-labeled anti-Ly6G (BioLegend) and PE-Cy7-conjugated anti-Ly6C (BioLegend). Subsets of MDSCs were sorted to a purity of > 90% using a BD FACSARia III cell sorter (BD Biosciences). For sorting of intratumoral DCs the enriched CD45^+ cells were stained with BV605-conjugated anti-CD45 (BD Biosciences) FITC-conjugated anti-CD11b (BD Biosciences), APC-labeled anti-Ly6C (BioLegend) and PE-Cy7-conjugated anti-Ly6C (BioLegend). Subsets of MDSCs were sorted to a purity of > 90% using a BD FACSARia III cell sorter (BD Biosciences). For sorting of intratumoral DCs the enriched CD45^+ cells were stained with BV605-conjugated anti-CD45 (BD Biosciences) FITC-conjugated anti-CD11b (BD Biosciences) and AF647-conjugated anti-mouse CD11c (BioLegend).

Suppression assay

The suppressive activity of MDSCs was determined using standard proliferation assays as described before [22]. Briefly, splenocytes were isolated from naive mice, labeled with 0.5 μM CellTrace® Violet (Invitrogen) and seeded in 96-well plates at 2 x 10^5 cells per well. Purified MDSCs were then added at different ratios (MDSC:splenocytes), 1:8 (spleen), 1:10 (subcutaneous tumor) and 1:4 (intracranial tumor). T-cell proliferation was induced by Dynabeads® Mouse T-activator CD3/CD28 beads (Invitrogen). After 3 days, proliferation of CD4^+ and CD8^+ T cells was analyzed by flow cytometry by staining with PerCPCy5.5-conjugated anti-mouse CD3 (BioLegend), AF700-conjugated anti-mouse CD4 (BD Biosciences) and APCH7-conjugated anti-mouse CD8 (BD Biosciences) antibodies. The percentage of T-cell suppression was calculated using the following formula:

% suppression = \[ \frac{1 - (\% \text{ proliferation with MDSC})}{\% \text{ proliferation without MDSC}} \times 100. \]

In addition, supernatants collected 3 days after co-culture were subjected to ELISA to quantify cytokine secretion.

DC stimulation assay

Spleen-derived pmel CD8^+ T cells were enriched by MACS sorting using CD8 MicroBeads (Miltenyi Biotec), were subsequently labeled with 0.5 μM CellTrace® Violet (Invitrogen) and seeded in 96-well plates. Purified DCs were then added at a 1:10 ratio (DC:splenocytes). After 3 days, proliferation of pmel CD8^+ T cells was analyzed by flow cytometry by staining with PerCPCy5.5-conjugated anti-mouse CD3 (BioLegend), AF700-conjugated anti-mouse CD4 (BD Biosciences) and APCH7-conjugated anti-mouse CD8 (BD Biosciences) antibodies. In addition, supernatants collected 3 days after co-culture were subjected to ELISA to quantify cytokine secretion.

Allogeneic mixed lymphocyte reaction

Spleen-derived CD8^+ T cells (from C3H mice) were enriched by MACS sorting using CD8 MicroBeads (Miltenyi Biotec), were subsequently labeled with 0.5 μM CellTrace® Violet (Invitrogen) and seeded in 96-well plates at 2 x 10^5 cells per well. Purified allogeneic monocytic MDSCs (sorted from tumors of C57BL/6 mice) were then added at different ratios 1:10, 1:20 and 1:40 (MDSC:splenocytes). After 3 days, proliferation of CD8^+ T cells was analyzed by flow cytometry by staining with PerCPCy5.5-conjugated anti-mouse CD3 (BioLegend), AF700-conjugated anti-mouse CD4 (BD Biosciences) and APCH7-conjugated anti-mouse CD8 (BD Biosciences) antibodies. In addition, supernatants were collected 3 days after co-culture were subjected to ELISA for determination of cytokine secretion by ELISA.
Combined VEGFR-CTLA-4 blockade and intratumoral DCs and MDSCs

Figure 1. Axitinib+αCTLA4 reduces tumor growth and increases survival in subcutaneous and intracranial mouse models. A. Treatment schedule of subcutaneous and intracranial tumor-bearing mice. C57BL/6 mice were subcutaneously or intracranially inoculated with B16F1 cells. For the subcutaneous model, treatment with axitinib was initiated when the tumor was palpable (+/- 150 mm$^3$) and for the intracranial model, treatment with axitinib was initiated when tumors emitted a bioluminescent signal. Vehicle or axitinib was given for a duration of 7 days through oral gavage at a dose of 25 mg/kg, bis in diem (bid). Isotype control or αCTLA4 was given intraperitoneally at a dose of 5 mg/kg on day 2, 4, 6 and 8 after initiation of axitinib treatment. B. Survival curve and mean tumor growth curve of the four treatment groups of the subcutaneous model (n = 2, 5 mice per group); *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. C. Survival curve and mean tumor growth curve represented as bioluminescent signal (radiance) of the intracranial model (n = 2, 6 mice per group); *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. D. Representative example of bioluminescence imaging of the intracranial tumors according to treatment group. One representative of 2 independent experiments is shown.
Figure 2. Axitinib+αCTLA4 increases the number of CD4+ and CD8+ T cells in the spleen of subcutaneous tumor-bearing mice. Subcutaneous tumor-bearing mice were treated with vehicle or axitinib for 7 days (25 mg/kg, oral gavage, bid). Isotype control of αCTLA4 was given on day 2, 4 and 6 after initiation of axitinib treatment (intraperitoneal (IP), 5 mg/kg). Mice were sacrificed on the 7th day of axitinib treatment and single cell suspensions of the spleen were made and subsequently analyzed through flow cytometry. A. Gating strategy for determination of the T cells. Percentage of CD45+ cells. Percentage of CD3+ cells within the CD45+ cell population. Percentage of CD8+ and CD4+ cells within the CD3+ cell population. Percentage of CD25+ cells within the CD4+ cell population. B.
Flow cytometry

Data were collected on an LSR Fortessa flow cytometer (BD Biosciences) and analyzed with FACSDiva (BD Biosciences) software.

ELISA

The concentration of interferon-gamma (IFN-γ) (eBioscience), tumor-necrosis factor-alpha (TNF-α) (eBioscience) and interleukin-2 (IL-2) (eBioscience) in culture supernatants was quantified using commercially available ELISA kits according to the manufacturer's instructions. The optical density was measured at 450 nm using a Thermomax microplate reader.

Statistical analysis

Results are presented as mean ± SEM. For the comparison of two groups, Student's t-test (unpaired T-test with equal standard deviation (SD)) was performed. Definition of statistical significance P < 0.05. Sample size and number of repetitions for each experiment are indicated in the figure legends. For tumor growth, a two-way ANOVA followed by the Bonferroni multiple comparison test was conducted (significance and confidence level: 0.05 (95% confidence interval)). Sample Survival was visualized in a Kaplan-Meier curve and analyzed by the log-rank (Mantel-Cox) test. All statistical analyses were performed using GraphPad Prism 6.

Results

Axitinib combined with αCTLA-4 reduces tumor growth and increases survival in subcutaneous and intracranial melanoma models

To investigate whether axitinib+αCTLA-4 combination treatment had an enhanced effect on tumor growth and survival compared to the respective monotherapies, we randomized subcutaneous and intracranial B16F1 tumor-bearing mice in four treatment groups: vehicle/isotype, vehicle/αCTLA-4, axitinib/isotype and axitinib/αCTLA-4 (Figure 1A). For the purpose of clarity and consistency, hereafter, we will refer to these groups as respectively control, αCTLA, axitinib and combination group.

Axitinib+αCTLA-4 treatment significantly inhibited tumor growth as compared to the control and αCTLA-4 groups in both the subcutaneous (Figure 1B) and intracranial (Figure 1C and 1D) models. In addition, in the subcutaneous model, there was a trend towards a reduction of tumor growth in the combination group as compared to the axitinib group. In contrast to the αCTLA-4 group, in the axitinib group, tumor growth was also significantly reduced as compared to the control group.

In both models, survival was significantly increased in the axitinib and axitinib+αCTLA-4 groups as compared to the control and αCTLA-4 groups (Figure 1B and 1C). In the intracranial model, we also found a significant survival benefit in the αCTLA-4 group when compared to the control group. Moreover, in the axitinib+αCTLA-4 group there was a significant increased survival as compared to the axitinib group (Figure 1C). Median survival in the axitinib+αCTLA-4 group was considerably longer as compared to the axitinib group in the subcutaneous model (resp. 37 days vs. 30 days (Figure 1B).

In conclusion, these results suggest that the combination of axitinib with αCTLA-4 leads to a stronger reduction in tumor growth and an increased survival in both subcutaneous and intracranial melanoma mouse models when compared to monotherapy with axitinib or αCTLA-4.

Addition of αCTLA-4 to axitinib treatment does not further increase the number of CD4+ and CD8+ T cells in the spleen of B16F1 subcutaneous tumor-bearing mice

We previously demonstrated that axitinib treatment increases the number of CD8+ T cells in the spleen of mice subcutaneously inoculated with the immunogenic MO4 (B16-OVA) tumor...
Combined VEGFR-CTLA-4 blockade and intratumoral DCs and MDSCs
cell line [16]. To assess whether combining axitinib with αCTLA-4 could further enhance these effects, we analyzed the spleen of mice subcutaneously inoculated with the poorly immunogenic B16F1 cell line.

In both the axitinib and the axitinib+αCTLA-4 group we found a significantly increased number of CD45^+ cells compared to the control and the αCTLA-4 group. In both groups we also found a significant increased number of CD3^+, CD4^+ and CD8^+ T cells as compared to the control and αCTLA-4 group (Figure 2A). However, an increased number of Treg was observed, which reached statistical significance for the axitinib+αCTLA-4 group as compared to the αCTLA-4 group (p = 0.0232) (Figure 2A). No significant differences were found in the other immune cells populations (CD11c^+ cells (DCs), CD11b^+ cells, CD11b^+Ly6C^hiLy6G^- cells (moMDSCs) or CD11b^+Ly6C^loLy6G^+ cells (grMDSCs)) (Figure 2B and 2C).

The addition of αCTLA-4 to axitinib treatment did not further increase the number of CD4^+ or CD8^+ T cells in the spleen.

αCTLA-4 alone or in combination with axitinib increases the presence of antigen-specific T cells in the spleen

Since we found an increased number of CD8^+ T cells in the spleen of tumor-bearing mice treated with axitinib+αCTLA-4, we investigated whether this treatment also affects the number of antigen-specific CD8^+ T cells in the spleen. Splenocytes were isolated from subcutaneous tumor-bearing mice and restimulated with Tyrosinase-Related Protein 2 (TRP-2) peptide. Due to its expression in both melanocytes and melanoma, TRP-2 is reported as a melanoma rejection antigen. Proliferation and cytokine secretion of CD8^+ T cells were evaluated after 72 h of restimulation. In the αCTLA-4 and axitinib+αCTLA-4 group we observed an increased proliferation accompanied by a significantly increased IFNγ, IL-2 and TNFα production in response to the TRP-2 peptide. This was even more pronounced in the combination group (Figure 4A).

These results suggest that αCTLA-4 increases the number of antigen-specific CD8^+ T cells in the spleen of tumor-bearing mice. This effect was maintained and enhanced when combined with axitinib treatment.

Axitinib combined with αCTLA-4 reduces the number of granulocytic MDSCs in subcutaneous tumors and increases the number of matured DCs in intracranial tumors

We further investigated the effect of these treatments on the immune cells present in the tumor microenvironment.

In the subcutaneous and intracranial tumors we observed a significant increase in the number of tumor-infiltrating immune cells in the axitinib and axitinib+αCTLA-4 group as compared to the control and αCTLA-4 group (Figure 3A and 3D). We found a significantly increased number of Treg in the axitinib+αCTLA-4 group as compared to the control and αCTLA-4 groups, respectively, in the subcutaneous model, but not in the intracranial model. No significant differences in the CD4^+ and CD8^+ T cells were found in the different treatment groups (Figure 3A and 3D).

Investigation of the DCs and their maturation markers showed a non-significant trend towards increased number of DCs in the αCTLA-4 and axitinib+αCTLA-4 group as compared to the control and axitinib group in the subcutaneous model. In those groups we also found an increased expression of maturation markers, which was significant in the axitinib+αCTLA-4 group.
Combined VEGFR-CTLA-4 blockade and intratumoral DCs and MDSCs
Combined VEGFR-CTLA-4 blockade and intratumoral DCs and MDSCs

Figure 4. Axitinib+αCTLA4 increases the number of antigen-specific CD8\(^+\) T cells within the spleen and increases the antigen-presenting function of intratumoral DCs. A. Subcutaneous tumor-bearing mice were treated with vehicle or axitinib for 7 days (25 mg/kg, oral gavage, bid). Isotype control or αCTLA4 was given on day 2, 4 and 6 after initiation of axitinib treatment (IP, 5 mg/kg). Mice were sacrificed on the 7th day of axitinib treatment and single cell suspensions of the spleen were made and CD8\(^+\) T cells were restimulated with TRP-2 (5 µM). Proliferation and cytokine production were analyzed after 72 h. Representative FACS profile of the determination of the CD8\(^+\) T-cell proliferation. Proliferation of CD8\(^+\) T cells after 72 h of restimulation expressed as mean fold increase. IFNγ, IL-2 and TNFα secretion as determined after 72 h of restimulation and expressed as mean fold increase. Controls included T cells cultured in the absence of MDSCs with and without T-cell stimulation. B (subcutaneous tumor) and C. (intracranial tumor) DCs were sorted from subcutaneous or intracranial tumor-bearing mice that were treated with vehicle or axitinib for 7 days (25 mg/kg, oral gavage, bid) and isotype control or αCTLA4 on day 2, 4 and 6 after initiation of axitinib treatment (IP, 5 mg/kg). These intratumoral DCs were co-cultured with CD8\(^+\) T cells sorted from the spleen of naïve pmel mice at a 1:10 ratio (DC:CD8\(^+\) T cells). Proliferation and cytokine production were analyzed after 72 h. Controls included T cells cultured in the absence of MDSCs with and without T-cell stimulation. Representative FACS profiles of the determination of CD8\(^+\) T-cell (pmel) proliferation. Proliferation of the CD8\(^+\) T cells after 72 h of co-culture expressed as mean fold increase. IFNγ, IL-2 and TNFα secretion as determined after 72 h of co-culture and expressed as mean fold increase. Three (or two for subcutaneous DCs) independent experiments were performed with 3 mice per group, spleens or tumors were pooled per group before cell sorting, and results are presented as mean ± SEM; *p < 0.05; **p < 0.01; ***p < 0.001.

Investigation of the CD11b\(^+\) cells, moMDSCs (CD11b\(^+\)Ly6G\(^-\)Ly6C\(^+\) cells) and grMDSCs (CD-11b\(^+\)Ly6C\(^-\)Ly6G\(^+\) cells) showed a significantly increased number of CD11b\(^+\) cells in the axitinib and axitinib+αCTLA4 group as compared to the control and αCTLA4 groups in the subcutaneous model and intracranial model. Moreover, in both tumor models we found a significantly increased number of moMDSCs in the axitinib and axitinib+αCTLA4 group as compared to the control and αCTLA4 group. Additionally, in the subcutaneous model we observed a significant reduction of the number of grMDSCs in the axitinib+αCTLA4 group as compared to the control group. In contrast, in the intracranial model, no significant reduction in the number of grMDSCs was observed in the treatment groups as compared to the control group (Figure 3C and 3F).

Overall, axitinib increases the number of tumor-infiltrating immune cells, more specifically CD11b\(^+\) cells and moMDSCs. This effect was maintained in the combination treatment. αCTLA4 increased the number of mature DCs in the subcutaneous model. The additional benefit of the combination treatment was translated in a significant reduction of the number of grMDSCs in the subcutaneous tumors and a significantly increased number of mature DCs in the intracranial tumor.

Axitinib combined with αCTLA-4 increases the antigen-presenting capacity of intratumoral DCs

Since we observed an increased number of mature DCs in the subcutaneous and intracranial tumors, respectively in the αCTLA-4 and axitinib+αCTLA4 group, we investigated whether the antigen-presenting function of these DCs was affected by the treatment. Therefore we sorted DCs from subcutaneous and intracranial tumors and co-cultured them with CD8\(^+\) T cells isolated from naïve pmel transgenic mice. Proliferation and cytokine secretion was analyzed after 72 h. In both subcutaneous and intracranial models, we found a significantly increased proliferation of CD8\(^+\) T cells in the axitinib+αCTLA-4 group as compared to the control group. This effect was not observed in the axitinib and αCTLA-4 group. This was accompanied by an increased production of IL-2 and TNFα in the axitinib+αCTLA-4 group (Figure 4B and 4C).

These results suggest that the combination of axitinib with αCTLA-4 increases the antigen-presenting capacity of intratumoral DCs.

Axitinib, αCTLA-4 and axitinib combined with αCTLA-4 lead to a reduced suppressive capacity of intratumoral moMDSCs

Since we have shown that addition of αCTLA-4 to axitinib treatment further increased the
Combined VEGFR-CTLA-4 blockade and intratumoral DCs and MDSCs

Figure 5. Axitinib+αCTLA4 reduces the suppressive capacity of moMDSCs sorted from the spleens of subcutaneous tumor-bearing mice and from the subcutaneous and intracranial tumors. Monocytic MDSCs were sorted from either the spleens of subcutaneous tumor-bearing mice or from the subcutaneous or intracranial tumors of mice.
treated with vehicle or axitinib for 7 days (25 mg/kg, oral gavage, bid) and isotype control or αCTLA4 on day 2, 4 and 6 after initiation of axitinib treatment (IP, 5 mg/kg). These moMDSCs were co-cultured with splenocytes isolated from the spleen of naive C57BL/6 mice at different moMDSC:T cell ratios in the presence of anti-CD3/CD28 beads. Proliferation and cytokine production were analyzed after 72 h. Controls included T cells cultured in the absence of MDSCs with and without T-cell stimulation. A. moMDSCs sorted from the spleen of tumor-bearing mice. Representative FACS profiles of the determination of the CD4+ and CD8+ T cell proliferation in a 1:8 (moMDSC:T cell) ratio. Percentage of suppression of moMDSCs on CD4+ and CD8+ T cells at a 1:8 ratio after 72 h of co-culture. IFNγ, IL-2 and TNFα secretion as determined after 72 h of co-culture. B. Intratumoral moMDSCs in the subcutaneous model. Representative FACS profiles of the determination of the CD4+ and CD8+ T cell proliferation in a 1:10 (moMDSC:T cell) ratio. Percentage of suppression of moMDSCs on CD4+ and CD8+ T cells at a 1:10 ratio after 72 h of co-culture. IFNγ, IL-2 and TNFα secretion as determined after 72 h of co-culture. C. Intratumoral moMDSCs in the intracranial model. Representative FACS profiles of the determination of the CD4+ and CD8+ T cell proliferation in a 1:4 (moMDSC:T cell) ratio. Percentage of suppression of moMDSCs on CD4+ and CD8+ T cells at a 1:4 ratio after 72 h of co-culture. IFNγ, IL-2 and TNFα secretion as determined after 72 h of co-culture. Two independent experiments were performed with 3 mice per group, spleens or tumors were pooled per group before cell sorting, and results are presented as mean ± SEM; *p < 0.05.

number of moMDSCs and since we previously showed that axitinib reduces the suppressive capacity of moMDSCs, we investigated whether axitinib+αCTLA-4 affected the suppressive function of moMDSCs. Therefore we sorted moMDSCs from the spleens of subcutaneous tumor-bearing mice and from the intracranial and subcutaneous tumors. We co-cultured these moMDSCs with stimulated splenocytes derived from naïve mice in a 1:8 (spleen), 1:10 (subcutaneous) and 1:4 (intracranial) ratio (moMDSC:T cell). After 72 h, proliferation and cytokine secretion were analyzed.

In the spleen we observed a significant reduction of the suppressive capacity of moMDSCs on CD8+ T cells in both the axitinib and axitinib+αCTLA-4 group. In the subcutaneous tumors we found a reduction of the suppressive capacity of these moMDSCs on CD8+ T cells in both the αCTLA-4 and axitinib group, but these were not statistically significant. However, when both treatments were combined, a stronger and significant reduction of the suppressive function was obtained. In both the spleen and the subcutaneous tumor, the reduction of the suppressive capacity was less pronounced on CD4+ T cells in the axitinib and αCTLA-4, but the suppressive function on CD4+ T cells is strongly reduced in the combination group. In the intracranial model, we found a strong reduction of the suppressive capacity of intratumoral moMDSCs in all treatment groups (Figure 5A-C).

When cytokine secretion was analyzed no significant changes were observed in all treatment groups (Figure 5A-C).

These results suggest that the combination of axitinib with αCTLA-4 reduces the suppressive capacity of moMDSCs sorted from the spleen, subcutaneous and intracranial tumors.

Axitinib, αCTLA-4 and axitinib combined with αCTLA-4 induce an antigen-presenting function in intratumoral monocytic MDSCs present in the subcutaneous tumor, but not in the intracranial tumors

Previously we have shown that axitinib induces an antigen-presenting function in moMDSCs sorted from MO4 subcutaneous tumors, but not from intracranial tumors [20]. Since we showed that the combination of axitinib with αCTLA-4 further reduces the suppressive capacity of intratumoral moMDSCs in the subcutaneous model, we investigated whether there was also an increased antigen-presenting capacity of these moMDSCs after axitinib+αCTLA-4 treatment. Therefore moMDSCs sorted from subcutaneous or intracranial tumors were co-cultured with CD8+ T cells isolated from naïve C3H mice at different ratios.

In the subcutaneous model, we observed an increase in CD8+ T-cell proliferation (Figure 6A) and cytokine secretion (IFNγ, IL-2 and TNFα) (Figure 6B) in the three treatment groups as compared to the control group. At a 1:10 ratio, we did not observe an additional effect of combining both treatments. However, at a 1:20 and 1:40 ratio we observed a more pronounced increase in the proliferation and cytokine secretion in the combination group.

However, in the intracranial tumor model we did not find specific differences between the different treatment groups (data not shown).

These results suggest that treatment with αCTLA-4, axitinib and especially with the com-

Am J Cancer Res 2016;6(11):2514-2531
Combined VEGFR-CTLA-4 blockade and intratumoral DCs and MDSCs

Discussion

In this study we show that the combination of axitinib with αCTLA-4 significantly increased survival in intracranial and subcutaneous melanoma mouse models. Moreover, we also demonstrate that axitinib combined with αCTLA-4 increases the antigen-presenting capacity of intratumoral DCs, reduces the number of grMDSCs and increases the number of moMDSCs with a reduced suppressive capacity in subcutaneous and intracranial tumors. However, an antigen-presenting capacity after axitinib+αCTLA-4 treatment was only induced in the moMDSCs isolated from subcutaneous tumors. Together these results demonstrate that the combination of VEGFR-blockade with CTLA-4-blockade enhances the antigen-specific antitumor immune response and skews the immunosuppressive tumor microenvironment towards an immune stimulating one.

To our knowledge this is the first time that the effect of the combination of VEGFR-blockade with CTLA-4-blockade on immune cells is extensively examined in subcutaneous and intracranial melanoma mouse models. Similar to
Combined VEGFR-CTLA-4 blockade and intratumoral DCs and MDSCs

our previous results obtained with axitinib in a more immunogenic MO4 (B16-OVA) model, we found that axitinib increased the number of CD4+ and CD8+ T cells in the spleen of subcutaneous tumor-bearing mice. The addition of αCTLA-4 treatment did not further increase the frequencies of T cells, but increased the number of antigen-specific CD8+ T cells in the spleen. These results are in line with previous findings, which show that CTLA-4 blockade induces an immune memory in preclinical models and increases the antigen-specific CD8+ T cell numbers in prevaccinated patients with melanoma [23, 24].

Several changes in the immune cell populations were found in the tumor microenvironment in the different treatment groups. Firstly, in the spleen and in the subcutaneous tumor we found a significantly increased number of Treg in the combination group. Since the markers we used to define Treg are shared with activated T cells, we sorted them from the spleen of these tumor-bearing mice. We did not find a significant reduction in the suppressive capacity of Treg in the several treatment groups (data not shown). Several studies demonstrated that αCTLA-4 treatment expends Treg in lymphoid organs and blood of both mice and humans [25, 26]. In contrast, when CTLA-4 blockade was combined with a vaccine consisting of irradiated tumor cells transduced to express GM-CSF (Gvax) an increased ratio of effector T cells to Treg was present in the tumor. The fact that we did not find this increased ratio in our treatment model is probably due to the absence of antigen-specific vaccination.

Secondly, CTLA-4 blockade in monotherapy and in combination with axitinib increased the number of mature DCs. When these were sorted from intracranial and subcutaneous tumors we observed a significantly increased antigen-presenting capacity in the combination group, but not in the αCTLA-4 or axitinib group. VEGF is known to inhibit the maturation of DCs and monoclonal antibodies against VEGF increased the endogenous DC function [12, 27]. In this study we mainly found a significantly increased antigen-presenting capacity when VEGFR-blockade was combined with CTLA-4 blockade. It has been shown that CTLA-4 reduced the expression of CD80 and CD86 on DCs through transendocytosis [28]. In this study we also demonstrate that CTLA-4 blockade increases the expression of CD80 and CD86 on intratumoral DCs. Furthermore, it has been shown that CTLA-4 is expressed by human DCs and influences their maturation and antigen presentation [29]. Combining VEGFR- and CTLA-4 blockade probably increases the DC maturation and their antigen-presenting capacity through reduction of these suppressive mechanisms.

Thirdly, a reduced number of grMDSCs was found in the subcutaneous tumors in the combination arm. In the intracranial tumors, this reduction was seen in all treatment groups. In melanoma patients it was shown that ipilimumab reduces the number and suppressive capacity of circulating grMDSCs [18]. However, in renal cell carcinoma patients treatment with bevacizumab did not decrease the number of MDSCs [30]. So, the effect of axitinib on these grMDSCs is probably indirect. In our study, we tried to investigate the suppressive capacity of these intratumoral grMDSCs, however we did not obtain a sufficient number of cells to perform functional assays (data not shown). In contrast to the grMDSCs, we observed an increased number of moMDSCs in the axitinib and axitinib+αCTLA-4 group. These results are consistent with our previous data obtained with axitinib in an immunogenic MO4 model.

Moreover, when these moMDSCs were sorted from the spleen, the subcutaneous or intracranial tumor, we found that they had a reduced suppressive capacity. Since there was no additional effect of the combination therapy in the spleen, this reduced suppressive capacity can be attributed to the effect of axitinib. In the subcutaneous and intracranial tumors, there was a reduction of the suppressive capacity in both the monotherapy groups and the combination group. We only found an additional reduction in the combination group in the subcutaneous tumor. In addition, in the subcutaneous tumor, these cells acquired an antigen-presenting function. To our knowledge this is the first time that the effect of CTLA-4 blockade with or without VEGFR-blockade on the function of moMDSCs has been studied. In melanoma patients, treatment with ipilimumab reduced the number of circulating moMDSC and a greater decrease was associated with an improved progression-free survival (PFS) [19]. In the subcutaneous model, we demonstrate that the moMDSCs acquired an antigen-presenting function in the
three treatment groups. However, this was not the case for the intracranial model. These results are consistent with our previous findings obtained with axitinib in the MO4 melanoma model. The fact that the moMDSCs sorted from intracranial tumors did not obtain an antigen-presenting function is probably related to the naturally immunosuppressive microenvironment of the central nervous system (anatomically protected by blood brain barrier, paucity of professional antigen presenting cells, low levels of Major Histocompatibility Complex (MHC) molecule expression and constitutive expression of immunosuppressive cytokines, such as IL-10 and TGF-β). In an ovarian carcinoma mouse model, it was shown that CTLA-4 is upregulated on the surface of MDSCs isolated out of the spleen of tumor-bearing mice and that CTLA-4 blockade reduces their arginase I production [31]. Despite the fact that the authors did not differentiate between granulocytic and monocytic MDSCs, this reduced arginase I production could be a possible mechanism for reduced suppressive function of moMDSCs in the intracranial model.

In conclusion, our results suggest that the supportive effect on tumor growth and survival of VEGFR- and CTLA-4 blockade is in part due to an enhanced antitumor immune response generated by an increased number of antigen-specific CD8+ T cells in the spleen and an increased antigen-presenting function of intratumoral DCs in combination with a reduction of the immunosuppressive tumor microenvironment, mainly the suppressive MDSCs. Although the combination treatment did not always lead to a significantly increased effect as compared to each treatment alone, our results suggest that an increased antitumor immune response can be obtained through combination of antiangiogenesis and immunotherapy. Currently multiple combinations with different immunotherapies are being investigated and further investigations are necessary to find the optimal combination treatment, especially in the treatment of melanoma brain metastases.

Acknowledgements

The authors thank Angelo Willems for expert assistance with the cell sorting. Sarah K Maenhout and Stephanie Du Four are funded by a PhD grant from the Agency for Innovation by Science and Technology in Flanders (IWT). This work is supported by a grant from the Research Foundation Flanders (Fonds voor Wetenschappelijk Onderzoek (FWO, G02341-1N)) to Kris Thielemans and Joeri L Aerts. The FACS AriaIII cell sorter and the LSR Fortessa were purchased with support from the Hercules Foundation to Kris Thielemans and Joeri L Aerts (grant UABR/09/002) and the Foundation against Cancer (Stichting Tegen Kanker), respectively.

Disclosure of conflict of interest

None.

Address correspondence to: Joeri L Aerts, Laboratory of Molecular and Cellular Therapy, Vrije Universiteit Brussel, Laarbeeklaan 103E, 1090 Jette, Belgium. Tel: +32-2 477 45 69; Fax: +32-2 477 45 68; E-mail: Joeri.Aerts@vub.ac.be

References

Combined VEGFR-CTLA-4 blockade and intratumoral DCs and MDSCs


Combined VEGFR-CTLA-4 blockade and intratumoral DCs and MDSCs


